NASDAQ NMS - GLOBAL MARKET · INAB
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
IN8bio Inc

IN8bio Inc

Biotechnology
$1.40
Card
Relationship Map

Follow $INAB

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $INAB by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
INAB
IN8bio Inc
Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Highest qualified

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

76/ 100
Veridion Score
Highest qualified · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is INAB moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading INAB catalysts
About IN8bio Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2021
Employees
18
Country
US

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.40
Last session
Day high
$1.40
Last session
Day low
$1.40
Last session
Previous close
$1.40
52W high
$2.59
-45.95% from high
52W low
$0.9600
27% of range
Market cap
$13.7M
EPS
$-2.0523
Beta
0.64
Shares out
9.9M
Avg volume
45.5K
VWAP
$1.40
Last session
Price history computed in-house
1W
0.00%
1M
+22.81%
3M
+5.26%
1Y
-41.91%
YTD
-40.17%
SMA 50 $1.14 · above
SMA 200 $1.54 · below
52W position 27%

INAB overview

Veridion Score
76
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around INAB.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading INAB Form 4 filings
Public disclosures

Congress activity in INAB

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

INAB contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for INAB in this window.
Lobbying spend

INAB lobbying filings, year to date.

Registered lobbying filings matched to IN8bio Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for INAB in this window.
Loading news for INAB
Analyst ratings
Sovereign unlock shows live analyst consensus for INAB.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.